Wells Fargo Sticks to Their Buy Rating for Ionis Pharmaceuticals Inc (IONS)

In a report released today, Jim Birchenough from Wells Fargo maintained a Buy rating on Ionis Pharmaceuticals Inc (IONSResearch Report). The company’s shares closed last Monday at $59.74.

According to TipRanks.com, Birchenough is a 5-star analyst with an average return of 18.8% and a 46.7% success rate. Birchenough covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics Inc, Akcea Therapeutics Inc, and Morphic Holding Inc.

Ionis Pharmaceuticals Inc has an analyst consensus of Hold, with a price target consensus of $67.86, which is a 14.1% upside from current levels. In a report released yesterday, Needham also reiterated a Buy rating on the stock with a $87.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $86.58 and a one-year low of $43.27. Currently, Ionis Pharmaceuticals Inc has an average volume of 1.02M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs.